Monish Bahl

Question 1

Monish Bahl's questions to XBiotech (XBIT) leadership • Q4 2016

Mar 16, 2017

Question

Monish Bahl from MHB Capital asked for an update on the data release timeline for the staph infection program and inquired about the company's strategy for partnering on late-stage programs to manage cash burn.

Answer

CEO John Simard responded that the staph infection data analysis is a priority and is expected to be completed and reported by the end of the month, following the EMA package submission. Regarding partnerships, Simard confirmed the company is open to various possibilities, stating that any potential deal would be driven by the specific opportunity rather than a predetermined focus on a particular program.

Ask Fintool Equity Research AI

Question 2

Monish Bahl's questions to XBiotech (XBIT) leadership • Q3 2016

Nov 15, 2016

Question

Monish Bahl from MHB asked about the company's cash position and expected cash burn over the next 6-12 months, the use of the at-the-market (ATM) facility, potential capital from partnerships, and whether the EMA might wait for data from the larger global study before making a decision.

Answer

Founder, President & CEO John Simard explained that cash burn is expected to drop dramatically as major capital investments and Phase III studies conclude. He clarified that the ATM facility was only tested with a small transaction and that a substantial fundraising effort is planned after the EMA decision. Mr. Simard also mentioned that while partnership discussions are active, no deal has been finalized. He asserted that there is no indication the EMA's decision is connected to or waiting for results from the separate global study.